StockData

Alvotech vs BioCryst Pharmaceuticals

ALVO and BCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALVO and BCRX compare

BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 19.7% for Alvotech).

BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALVOBCRX
Size and price
Market cap–$1.9B
Share price$4.37$7.50
Change, 1 year−20.4%5.9%
Change, 5 years−55.8%−39.9%
Beta (5Y)0.370.58
Employees1,000435
StockData Score
Total score39 (better)
Valuation score01 (better)
Growth score24 (better)
Performance score02 (better)
Health score12 (better)
Dividend score00
Valuation
P/S–2.0×
P/FCF–5.1×
FCF yield–19.5%
Growth
Revenue growth (TTM)19.7%68.7% (better)
Revenue growth, 5Y average54.5%118% (better)
Profitability
Gross margin59.8%97.8% (better)
Operating margin13.3% (better)−33.3%
Net margin–−40.9%
FCF margin−19.6%39.7% (better)
Financial health
Net debt / EBITDA10.02–
Interest coverage0.5× (better)−4.2×
Current ratio1.652.32 (better)
Altman Z-score–−3.83
Piotroski F-score–7
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–103%
Held by insiders67.7%1.9%
Insider net buying, 12 months–−$4.1M
Short interest, % of float–11.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.